Taylor Swift’s team recently filed new trademark applications for two sound marks for Taylor’s voice, and one design mark for a glittering image from the Eras Tour:
Trademark U.S. Serial No. 99/784,977
AbbVie Submits Regulatory Application to FDA for Subcutaneous SKYRIZI
On April 27, 2026, AbbVie announced that it has submitted a regulatory application to the FDA seeking approval for SKYRIZI (risankizumab-rzaa) for subcutaneous induction for the treatment of adult patients with moderately to severely active Crohn’s disease. AbbVie states that its application is supported by positive data
According to Cisco Talus researchers, phishing is the primary method threat actors use to gain unauthorized access to networks, accounting for more than one-third of all incidents in the first quarter of 2026. This increase is attributed to threat actors using legitimate AI tools to enhance phishing campaigns, particularly against health care and government sectors.
Multiple class action cases have been filed against Tempus AI alleging that, during its acquisition of Ambry Genetics, the company improperly collected and disclosed genetic information without obtaining prior written consent from individuals during its acquisition of Ambry. Tempus acquired Ambry, a genetic testing firm, in February 2025 for $600 million. The acquisition included the
Talks between European Union legislators broke down on Wednesday as they tried to agree on proposed amendments to the EU AI Act. At the center of the debate is the Digital Omnibus on AI, first introduced in November 2025, which would delay several key compliance deadlines under the Act.
If approved, the Digital Omnibus would
Legal commentary on artificial intelligence in law practice often focuses on speed: drafts that once took days can now be produced in hours, and research that once took hours can now be narrowed in minutes. Those gains are real, but they do not resolve the more important operational questions. Many firms still don’t know whether
On April 15, 2026, the European Data Protection Board (EDPB) adopted guidelines on the processing of personal data for scientific research purposes.[1] The guidelines aim to clarify GDPR compliance requirements for scientific research involving personal data.
An AI governance policy defines how AI is managed across the organization. It is the starting point for meeting current insurance expectations and reducing underwriting friction. Underwriters no longer accept informal oversight. They expect a documented system showing where AI is used, how it is approved, and who is accountable for its operation.
At a minimum, this includes
AI compliance and insurance are now directly connected. Most companies assume their existing insurance covers AI-related risks. That assumption became wrong in 2026. The “silent AI” era is over. Until recently, AI risks were absorbed into existing policies because nothing explicitly excluded them. Coverage existed by default, not by design.
AI insurance requirements changed when insurers
PatentNext Takeway: Ex parte Desjardins—and especially the USPTO’s decision to make it precedential—appears to be shifting examination away from § 101 and toward § 112 written-description scrutiny, particularly for AI-related inventions. For AI-related inventions, a central takeaway is that practitioners should expect more examiner demands for concrete disclosure of how an AI model is trained,